Skip to content
10-Q

Quarterly Report

PROPANC BIOPHARMA, INC. PPCB

0001641172-25-010798

← back to feed
Filed
May 15, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2025 · May 15, 2025 11.61M sh
Long Term Debt Q3 2025 · Mar 31, 2025 $438.58K
Long Term Debt Q3 2025 · Jun 30, 2024 $399.33K
Current Liabilities Q3 2025 · Mar 31, 2025 $4.34M
Current Liabilities Q3 2025 · Jun 30, 2024 $3.79M
Total Liabilities Q3 2025 · Mar 31, 2025 $4.44M
Total Liabilities Q3 2025 · Jun 30, 2024 $3.85M
Current Assets Q3 2025 · Mar 31, 2025 $9.74M
Current Assets Q3 2025 · Jun 30, 2024 $25.44K
Total Assets Q3 2025 · Mar 31, 2025 $22.53M
Total Assets Q3 2025 · Jun 30, 2024 $72.37K
Shares Diluted restated Q3 2025 · Mar 31, 2024 994 sh
Shares Diluted restated Q3 2025 · Mar 31, 2024 523 sh
Operating Cash Flow Q3 2025 · Mar 31, 2024 −$675.15K
Stockholders Equity Q3 2025 · Mar 31, 2024 −$3.7M
Stockholders Equity Q3 2025 · Dec 31, 2023 −$3.56M
Stockholders Equity Q3 2025 · Sep 30, 2023 −$2.99M
Stockholders Equity Q3 2025 · Jun 30, 2023 −$3.12M
Eps Diluted restated Q3 2025 · Mar 31, 2024 −$545.79
Eps Diluted restated Q3 2025 · Mar 31, 2024 −$3,164.41
Eps Basic restated Q3 2025 · Mar 31, 2024 −$545.79
Eps Basic restated Q3 2025 · Mar 31, 2024 −$3,164.41
Sga Expense Q3 2025 · Mar 31, 2024 $348.84K
Sga Expense Q3 2025 · Mar 31, 2024 $1.06M
Rd Expense Q3 2025 · Mar 31, 2024 $65.45K
Rd Expense Q3 2025 · Mar 31, 2024 $195.71K
Net Income Q3 2025 · Mar 31, 2024 −$526.7K
Net Income Q3 2025 · Mar 31, 2024 −$1.46M
Net Income Q3 2025 · Dec 31, 2023 −$584.38K
Net Income Q3 2025 · Sep 30, 2023 −$350.87K
Operating Income Q3 2025 · Mar 31, 2024 −$420.87K
Operating Income Q3 2025 · Mar 31, 2024 −$1.28M